We can then confirm these suspicions with CDR2 and CDR2L antigen expression and genomic alterations and the presence of the anti-Yo antibody. Recognizing the symptoms of PCD and ordering the appropriate genomic and proteomic testing may facilitate early diagnosis and, consequently, an improvement in prognosis. This evidence concerns the gene CDR2 and paraneoplastic neurologic syndrome.